Group 1 - Zhongmin Resources has completed the construction of a 30,000-ton high-purity lithium salt project, which began trial production on January 2, 2026, with a total investment of 121 million yuan [2] - Shaoyang Hydraulic's acquisition of 100% of Chongqing Xincheng Hangrui Technology has been accepted by the Shenzhen Stock Exchange [3] - Xingqi Eye Medicine received approval for the supplementary application of atropine sulfate eye drops, aimed at delaying myopia progression in children aged 6 to 12 [4] Group 2 - Bailong Oriental expects a net profit of 600 million to 700 million yuan for 2025, representing a year-on-year increase of 46.34% to 70.73% [5] - Magmite's application for a private placement has been approved by the China Securities Regulatory Commission [6] - *ST Aowei's stock may face delisting risk due to a market capitalization below 500 million yuan [7] Group 3 - Changyuan Power plans to invest 572 million yuan in a wind power project in Hubei Province, with a planned capacity of 100 MW [8] - Haizheng Pharmaceutical's shareholder intends to transfer 6.06% of the company's shares [9] - Fusheng Technology has received approval for a share issuance to acquire assets and raise matching funds [10] Group 4 - Tenglong Co. plans to establish a joint venture for a liquid cooling company with an investment of 30 million yuan [11] - *ST Tianshan reported sales of live livestock amounting to 24.6 million yuan in December 2025, with significant year-on-year growth [12] - Hengxin Oriental's controlling shareholder has released a pledge of 0.91% of shares [13] Group 5 - Peking University Pharmaceutical plans to distribute a cash dividend of 1.68 yuan per 10 shares, totaling 100 million yuan [14] - Tianlong Co. intends to acquire a 54.87% stake in Suzhou Haomi Bo for 232 million yuan [15] - Jinggong Technology's first carbon fiber production line has successfully commenced trial production [16] Group 6 - Shanfeng Cement has terminated its investment and asset acquisition plans due to disagreements on asset valuation [17] - Shengyang Co. plans to acquire 51% of Shenzhen Daren High-tech for approximately 74.47 million yuan [18] - Xinxiang Chemical has resumed production of biomass cellulose filament after equipment upgrades [19] Group 7 - Jiuding New Materials plans to invest 246 million yuan in a wind turbine blade production line project [20] - Hunan Baiyin's shareholder has reduced its stake to below 5% [21] - Century Huatong intends to repurchase shares worth 300 million to 600 million yuan [22] Group 8 - Jincai Hulin plans to acquire 51% of Wuxi Sanli for 63.43 million yuan [23] - Jiamei Packaging's stock has experienced abnormal trading fluctuations, but no significant undisclosed information has been found [25] - Guoguang Electric's general manager has resumed duties after the lifting of restrictions [26] Group 9 - Shengxing Co. is planning a private placement for 2025, with no significant changes in its operational situation [27] - *ST Meigu has applied to lift the delisting risk warning after completing its restructuring plan [28] - CATL has repurchased 15.99 million A-shares for a total of 4.386 billion yuan [29] Group 10 - Phoenix Shipping's actual controller has been released from mandatory measures [30] - Guoxin Technology's new neural network processor has successfully passed internal testing [31] - Yanjing Co. plans to acquire control of Ningbo Yongqiang Technology, leading to a stock suspension [32]

Core Viewpoint - The company, Peking University Pharmaceutical (北大医药), announced a profit distribution plan for the first three quarters of 2025, aiming to enhance investor confidence and respond to regulatory calls for high-quality capital market development [1] Group 1: Profit Distribution Plan - The profit distribution plan involves a cash dividend of 1.68 yuan (including tax) for every 10 shares, totaling approximately 100 million yuan (including tax) [1] - The plan is based on the total share capital as of September 30, 2025, and is intended to reward all shareholders [1] Group 2: Strategic Intent - The company emphasizes its commitment to returning value to investors and society, aligning with the guidelines from the State Council on strengthening regulation and preventing risks [1] - The board of directors has proposed this plan while ensuring compliance with profit distribution principles and maintaining the company's normal operations and long-term development [1]

Core Viewpoint - The company aims to reduce operational uncertainties related to its reliance on the leasing of production assets from Daxin Pharmaceutical by strategically investing in the raw material pharmaceutical industry, thereby enhancing the stability and continuity of its production system [1] Group 1: Strategic Investment - The company plans to use its own funds to publicly bid for a 9.75% stake in Daxin Pharmaceutical held by Southwest Synthesis, with the transaction price based on an asset evaluation report [2] - The estimated value of Daxin Pharmaceutical's total equity is 232.5 million yuan, with the assessed value of the 9.75% stake being approximately 22.6688 million yuan [2] Group 2: Industry Collaboration - By deepening collaboration within the upstream supply chain, the company expects to directly benefit from the potential profit increases associated with the positive development trends in the raw material pharmaceutical industry [1] - This strategic move is anticipated to optimize the company's overall profitability and achieve a win-win situation within the industry chain [1]

Core Viewpoint - North China Pharmaceutical (000788.SZ) announced a profit distribution plan for the first three quarters of 2025, proposing a cash dividend of 1.68 yuan per 10 shares, totaling 100,125,887.40 yuan, to be distributed to all shareholders [1] Group 1 - The profit distribution plan is based on a total share capital of 595,987,425 shares as of September 30, 2025 [1] - The distribution will not include stock dividends or capital reserve transfers to increase share capital [1] - Any changes in total share capital due to convertible bonds, share buybacks, equity incentives, or refinancing will lead to adjustments in the distribution ratio while keeping the total distribution amount unchanged [1]

格隆汇1月4日丨北大医药(000788.SZ)公布，本次利润分配预案为2025年前三季度利润分配预案。公司 利润分配预案为：以2025年9月30日的总股本595,987,425股为基数,以可供股东分配的利润向公司全体股 东每10股派发现金1.68元（含税），总计派发红利100,125,887.40元（含税），剩余未分配利润结转以后 年度分配。本次利润分配不送红股，不以资本公积金转增股本。若在分配预案实施前公司总股本由于可 转债、股份回购、股权激励、再融资新增股份上市等原因发生变化的，将按照分配总额不变的原则对分 配比例进行调整。 ...

Group 1 - The company plans to acquire a 9.75% stake in Daxin Pharmaceutical for no more than 22.6688 million yuan [1] - Upon completion of the transaction, the company will hold a 9.75% equity interest in Daxin Pharmaceutical [1] - This transaction is classified as a related party transaction but does not constitute a major asset reorganization [1] Group 2 - Daxin Pharmaceutical is a key high-tech enterprise under the National Torch Program, primarily engaged in the research and production of active pharmaceutical ingredients and intermediates [1] - The company’s product range includes nutritional drugs, lipid-regulating agents, and antibiotics, and it also engages in CDMO (Contract Development and Manufacturing Organization) collaboration [1]

证券代码：000788 证券简称：北大医药 公告编号：2025-099 北大医药股份有限公司 关于公司以公开竞拍方式购买股权暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易基本情况概述 北大医药股份有限公司 董 事 会 二、关联交易进展情况 鉴于公司十一届董事会十七次会议已审议通过《关于同意公司以公开竞拍的 方式购买股权暨关联交易的议案》，公司于近日通过京东资产交易平台参与了大 新药业 9.75%股权的公开竞拍活动，并以 2,200 万元获拍价成功竞得大新药业 9.75%的股权。 三、本次关联交易对公司的影响 公司使用自有资金通过公开竞拍方式购买西南合成所持大新药业 9.75%股 份，该关联交易不存在损害公司及全体股东利益的情形，不会对公司的财务状况、 经营成果造成不利影响。 公司本次关联交易是为有效应对现阶段对大新药业核心生产资产存在的租 赁依赖，降低因该租赁关系可能引致的经营不确定性。公司计划通过战略性股权 投资等方式深度参与原料药产业经营，旨在强化公司生产体系的连续性与稳定 性，保障生产安全与长期战略的有效执行。通过深化 ...

北大医药股份有限公司（以下简称"公司"）根据《深圳证券交易所股票上 市规则》（以下简称"《股票上市规则》"）、《公司章程》等相关要求并结合 公司实际需要，对 2026 年度与重庆西南合成制药有限公司（以下简称"重庆合 成"）日常关联交易情况进行预计。预计公司 2026 年与重庆合成日常关联交易 总金额在不超过人民币 1,601 万元的范围内进行。 证券代码：000788 证券简称：北大医药 公告编号：2025-097 北大医药股份有限公司 关于公司 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、2026 年度公司与重庆西南合成制药有限公司日常关联交易预计的基本 情况 （一）基本情况概述 （二）履行的审议程序 公司于 2025 年 12 月 29 日召开第十一届董事会第十七次会议，审议通过了 《关于公司 2026 年度与重庆西南合成制药有限公司日常关联交易预计的议案》。 该议案的董事会表决情况为：赞成票 8 票，反对票 0 票，回避票 0 票，弃权票 0 票。该议案涉及关联交易，关联董事徐晰人先生回避表决，8 名非关联 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 （一）基本情况 为满足公司及全资子公司的生产经营需要，公司及全资子公司拟申请银行综 合授信额度 8 亿元人民币。公司为全资子公司北京新优势医药商业有限公司（以 下简称"北京新优势"）和北大医药武汉有限公司（以下简称"武汉公司"）申 请的综合授信额度提供保证担保，预计新增担保总额度不超过 3 亿元人民币。具 体担保金额及保证期间按照合同约定执行。授信期限内，授信额度可循环使用。 证券代码：000788 证券简称：北大医药 公告编号：2025-098 北大医药股份有限公司 关于公司2026年度银行授信融资计划暨提供担保的公告 （二）履行的审议程序 公司于 2025 年 12 月 29 日召开第十一届董事会第十七次会议审议通过了《关 于公司 2026 年度银行授信融资计划暨提供担保的议案》，该议案的董事会表决 情况为：赞成票 9 票，反对票 0 票，回避票 0 票，弃权票 0 票。该议案已经独立 董事专门会议、董事会审计委员会审议通过。相关情况参见公司同日在巨潮资讯 网（http://www.cninfo.c ...

证券代码：000788 证券简称：北大医药 公告编号：2025-095 北大医药股份有限公司 关于同意公司以公开竞拍方式购买股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： ● 关联交易事项：北大医药股份有限公司（以下简称"北大医药"或"公 司"）拟使用自有资金通过公开竞拍方式购买西南合成医药集团有限公司（以 下简称"西南合成"）所持北大医药重庆大新药业股份有限公司（以下简称"大 新药业"）9.75%股份（以下简称"交易标的"）。 ● 交易标的权属状况及风险提示：截止本公告披露日，交易标的处于质押 登记状态，本次关联交易中的交易相关方正积极协调并配合完成交易标的的质 权解押手续，解押完成时间可能存在一定不确定性，但整体风险可控。交易标 的未涉及司法查封、冻结等措施。公司使用自有资金通过公开竞拍方式购买西 南合成所持大新药业 9.75%股份，该关联交易不存在损害公司及全体股东利益的 情形，不会对公司的财务状况、经营成果造成不利影响。 一、关联交易概述 公司为有效应对现阶段对大新药业生产资产存在的持续性租赁依赖，降低因 该租赁关 ...